AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12947997 — intervention group
Group type: COMPARATOR
Intervention: Injection immunotherapy
Number of subjects: 0
Study 11028131 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNβ‐1b)
Number of subjects: 2000
Study 8826307 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Care Practice Model (PIPC)
Number of subjects: 0
Study 1576099 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-SR (10 mg b.i.d)
Number of subjects: 10
Study 1576099 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-SR
Number of subjects: 10
Study 2867037 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 683
Study 2867037 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 683
Study 31097338 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin fluid bolus therapy
Number of subjects: 100
Study 31097338 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid fluid bolus therapy
Number of subjects: 100
Study 30315670 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of DHEA for 28 days
Number of subjects: 11
Study 30315670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30315670 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA administration
Number of subjects: 11
Study 30315670 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA and T concentrations
Number of subjects: 11
Study 27010682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone gas bath combined with EVLT
Number of subjects: 92
Study 27010682 — intervention group
Group type: COMPARATOR
Intervention: EVLT alone
Number of subjects: 92
Study 24981311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/leucovorin/5-FU (FLP)
Number of subjects: 72
Study 24981311 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/leucovorin/oxaliplatin (FLO)
Number of subjects: 72
Study 22177821 — intervention group
Group type: COMPARATOR
Intervention: Propofol-saline solution admixture (Group A - Control)
Number of subjects: 64
Study 22177821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10:1 propofol-ketamine ratio (Group B)
Number of subjects: 64
Study 22177821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:1 propofol-ketamine ratio (Group C)
Number of subjects: 64
Study 22177821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 propofol-ketamine ratio (Group D)
Number of subjects: 64
Study 20451469 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 20451469 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at specific points
Number of subjects: 0
Study 20451469 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in neurotransmitters and biological response modifiers
Number of subjects: 0
Study 18398639 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoStop (mechanical compression)
Number of subjects: 77
Study 18398639 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioSeal (anchor and collagen sponge)
Number of subjects: 77
Study 18398639 — intervention group
Group type: EXPERIMENTAL
Intervention: Perclose (nonabsorbable suture)
Number of subjects: 77
Study 15973831 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype power toothbrush (Blend‐a‐Med Power)
Number of subjects: 86
Study 15973831 — intervention group
Group type: COMPARATOR
Intervention: Control manual toothbrush (Lion Dentor Systema)
Number of subjects: 86
Study 12818953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg intranasal hydromorphone hydrochloride
Number of subjects: 24
Study 12818953 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg intranasal hydromorphone hydrochloride
Number of subjects: 24
Study 12818953 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mg intravenous hydromorphone hydrochloride
Number of subjects: 24
Study 10784386 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photochemotherapy (ECP)
Number of subjects: 0
Study 10784386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7960542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-Yag laser treatment
Number of subjects: 116
Study 7960542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-Yag laser treatment combined with transurethral resection (TUR)
Number of subjects: 116
Study 7960542 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 116
Study 3110444 — intervention group
Group type: EXPERIMENTAL
Intervention: ProcalAmine (3% amino acids, 3% glycerol, and electrolytes)
Number of subjects: 25
Study 3110444 — intervention group
Group type: COMPARATOR
Intervention: FreAmineIII + dextrose and electrolytes
Number of subjects: 25
Study 31885129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored Planning to Be Active (MBA)
Number of subjects: 0
Study 31885129 — intervention group
Group type: COMPARATOR
Intervention: Planning to Be Active (PBA)
Number of subjects: 0
Study 29705707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at 60 mg/dL
Number of subjects: 148
Study 29705707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 26884472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg)
Number of subjects: 48
Study 26884472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (3 mg)
Number of subjects: 48
Study 26884472 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (weight-based dose)
Number of subjects: 48
Study 26884472 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 48
Study 26884472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg and 3 mg)
Number of subjects: 48
Study 27403406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/mL), administered via intratympanic injection, 0.5 ml, once every 2 days for 3 times
Number of subjects: 50
Study 27403406 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg/mg), administered via intratympanic injection, 0.5 ml, along with bicarbonate
Number of subjects: 50
Study 22833175 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head-cooling treatment (therapeutic hypothermia)
Number of subjects: 14
Study 22833175 — intervention group
Group type: COMPARATOR
Intervention: Control (rectal temperature 37°C)
Number of subjects: 14
Study 21830388 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating lunch before colonoscopy
Number of subjects: 0
Study 21830388 — intervention group
Group type: COMPARATOR
Intervention: Fasting before colonoscopy
Number of subjects: 0
Study 19863361 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 250/50
Number of subjects: 797
Study 19863361 — intervention group
Group type: COMPARATOR
Intervention: SAL
Number of subjects: 797
Study 16759927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches (300 microg T daily)
Number of subjects: 52
Study 16759927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15025600 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg kg(‐1) of aminophylline
Number of subjects: 60
Study 15025600 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 11708704 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g per day for 6 days)
Number of subjects: 19
Study 11708704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10380782 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfume exposure during airway exposure (with eyes covered)
Number of subjects: 11
Study 10380782 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfume exposure during eye exposure (with fresh air inhaled)
Number of subjects: 11
Study 10380782 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure (control)
Number of subjects: 11
Study 7711763 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm positive heel inclination
Number of subjects: 15
Study 7711763 — intervention group
Group type: COMPARATOR
Intervention: 0 heel inclination
Number of subjects: 15
Study 10313784 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School program
Number of subjects: 0
Study 10313784 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 826516 — intervention group
Group type: EXPERIMENTAL
Intervention: One Prompt plus $5 Incentive
Number of subjects: 51
Study 826516 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Prompt (Note, Telephone Contact, Home Visit)
Number of subjects: 51
Study 826516 — intervention group
Group type: COMPARATOR
Intervention: Note Only
Number of subjects: 51
Study 826516 — intervention group
Group type: COMPARATOR
Intervention: Three-Prompt
Number of subjects: 51
Study 31281111 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Meter Walking Test (10MWT) - first trial
Number of subjects: 50
Study 31281111 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Meter Walking Test (10MWT) - second trial
Number of subjects: 50
Study 31281111 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability measures
Number of subjects: 50
Study 28333318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily (10 mg three times daily)
Number of subjects: 1031
Study 28333318 — intervention group
Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP) 600 mg daily (200 mg three times daily)
Number of subjects: 1031
Study 28333318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 1031
Study 28333318 — intervention group
Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP)
Number of subjects: 1031
Study 25973439 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg BID
Number of subjects: 504
Study 25973439 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 504
Study 25973439 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 504
Study 23039088 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg twice daily)
Number of subjects: 24
Study 23039088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22078686 — intervention group
Group type: EXPERIMENTAL
Intervention: Woodstove with chimney (n=269)
Number of subjects: 534
Study 22078686 — intervention group
Group type: COMPARATOR
Intervention: Open woodfires (n=265)
Number of subjects: 534
Study 19907956 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Aspiration (PNA)
Number of subjects: 72
Study 19907956 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Catheter Drainage (PCD)
Number of subjects: 72
Study 16289977 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 24
Study 16289977 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol oil
Number of subjects: 24
Study 12852715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0
Study 12852715 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study 10691232 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 50
Study 10691232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside administration
Number of subjects: 50
Study 10691232 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive insulation)
Number of subjects: 50
Study 9313323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal penile tumescence monitoring by RigiScan device
Number of subjects: 64
Study 9313323 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary diagnostic approach (including dynamic color Doppler sonography and pharmaco-cavernosometry)
Number of subjects: 64
Study 8490070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency marijuana cigarettes
Number of subjects: 35
Study 8490070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potency marijuana cigarettes
Number of subjects: 35
Study 8490070 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 35
Study 3492950 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole, 320 mg/d-1600 mg/d for 2 or 6 weeks
Number of subjects: 60
Study 3492950 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, 2 g/d for 2 or 6 weeks
Number of subjects: 60
Study 29476079 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-localization methods to identify eQTL-meQTL pairs
Number of subjects: 0
Study 29476079 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-localization methods
Number of subjects: 0
Study 27455155 — intervention group
Group type: EXPERIMENTAL
Intervention: Teres ligament coverage
Number of subjects: 152
Study 24973959 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg once daily)
Number of subjects: 0
Study 24973959 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2 once weekly)
Number of subjects: 0
Study 24973959 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 24973959 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 22179956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (mean 1.06 hypoglycemic episodes in 7 days)
Number of subjects: 10096
Study 22179956 — intervention group
Group type: COMPARATOR
Intervention: Standard group (mean 0.29 hypoglycemic episodes in 7 days)
Number of subjects: 10096
Study 22179956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (5.8% unrecognized hypoglycemia at visits)
Number of subjects: 10096
Study 22179956 — intervention group
Group type: COMPARATOR
Intervention: Standard group (2.6% unrecognized hypoglycemia at visits)
Number of subjects: 10096
Study 20125186 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC)
Number of subjects: 20
Study 20125186 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC)
Number of subjects: 20
Study 18305548 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 36
Study 18305548 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 36
Study 18305548 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 15943857 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 57
Study 15943857 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 57
Study 12615792 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide (100 to 125 mg once daily for 6 or 9 months)
Number of subjects: 1380
Study 12615792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380
Study 12615792 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 1380
Study 10228046 — intervention group
Group type: EXPERIMENTAL
Intervention: rhumAb-E25 infusions biweekly for 46 weeks
Number of subjects: 0
Study 10228046 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of rhumAb-E25 infusions
Number of subjects: 0
Study 10228046 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophils cultured with IgE
Number of subjects: 0
Study 10228046 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophils cultured without IgE
Number of subjects: 0
Study 10228046 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophils cultured with IgG
Number of subjects: 0
Study 8924256 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief group counseling (3-hour skills training)
Number of subjects: 329
Study 8924256 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 329
Study 2029988 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha-2b
Number of subjects: 21
Study 2029988 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone (after a 6 wk course)
Number of subjects: 21
Study 2029988 — intervention group
Group type: COMPARATOR
Intervention: HLA class I antigen on hepatocytes
Number of subjects: 21
Study 7122702 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable rigid dressing
Number of subjects: 0
Study 7122702 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastic bandages
Number of subjects: 0
Study 31202210 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy combined with cryotherapy (MT-C)
Number of subjects: 128
Study 31202210 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy combined with cryotherapy (KIN-C)
Number of subjects: 128
Study 28644246 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital exercise intervention during neoadjuvant chemotherapy
Number of subjects: 20
Study 28644246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 20
Study 26444846 — intervention group
Group type: EXPERIMENTAL
Intervention: Infórmate website exposure
Number of subjects: 282
Study 26444846 — intervention group
Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 282
Study 24474552 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull (355 mL)
Number of subjects: 25
Study 24474552 — intervention group
Group type: COMPARATOR
Intervention: Tap water (355 mL)
Number of subjects: 25
Study 21961239 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of 2 ml of 80,000 U gentamycin + 2 ml of lidocaine, twice a week for 3 weeks
Number of subjects: 163
Study 21961239 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group B)
Number of subjects: 163
Study 21961239 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group C)
Number of subjects: 163
Study 19105706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0
Study 19105706 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg/day)
Number of subjects: 0
Study 17344487 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Calcium meal (MC meal: 84 mg/MJ)
Number of subjects: 18
Study 17344487 — intervention group
Group type: EXPERIMENTAL
Intervention: High Calcium meal (HC meal: 172 mg/MJ)
Number of subjects: 18
Study 17344487 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate supplement (Suppl meal: 183 mg/MJ)
Number of subjects: 18
Study 15550602 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk flexion over 45 degrees for 1 hour and 45 minutes per week (90th centile)
Number of subjects: 523
Study 15550602 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 523
Study 15550602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low decision authority and high work demands (psychosocial factors)
Number of subjects: 523
Study 15550602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical factors
Number of subjects: 523
Study 11560848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided stent implantation
Number of subjects: 550
Study 11560848 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided stent implantation
Number of subjects: 550
Study 9476460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestroft test in Group I (beta-thalassemia major families)
Number of subjects: 253
Study 9476460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestroft test in Group II (normal children)
Number of subjects: 253
Study 7700069 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0
Study 2444241 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural administration of meptazinol 90 mg
Number of subjects: 32
Study 2444241 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of meptazinol 90 mg
Number of subjects: 32
Study 31388637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline
Number of subjects: 69
Study 31388637 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 69
Study 31388637 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 69
Study 29706497 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training after RYGB
Number of subjects: 60
Study 29706497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 60
Study 29706497 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB (surgery)
Number of subjects: 60
Study 26391263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TXA (1 g IV + 2 g local)
Number of subjects: 210
Study 26391263 — intervention group
Group type: COMPARATOR
Intervention: IV TXA (1.5 g)
Number of subjects: 210
Study 26391263 — intervention group
Group type: COMPARATOR
Intervention: Local TXA (3 g)
Number of subjects: 210
Study 24206971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel post CABG
Number of subjects: 953
Study 24206971 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel post CABG
Number of subjects: 953
Study 22935812 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver (PRM)
Number of subjects: 81
Study 22935812 — intervention group
Group type: COMPARATOR
Intervention: Brandt-Daroff exercise (B-D exercise)
Number of subjects: 81
Study 19615825 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free, various flavors and brands)
Number of subjects: 177
Study 18793929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonics and rotary nickel‐titanium instruments (group B)
Number of subjects: 93
Study 18793929 — intervention group
Group type: COMPARATOR
Intervention: Rotary instruments alone (group A)
Number of subjects: 93
Study 15915009 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol via HFA pMDI
Number of subjects: 500
Study 15915009 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via DPI
Number of subjects: 500
Study 15915009 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol via HFA pMDI and DPI
Number of subjects: 500
Study 12604935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 0
Study 12604935 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured home blood pressure measurements
Number of subjects: 0
Study 12604935 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory white-coat hypertension (WCH)
Number of subjects: 0